DNA X approves cash grants to board, incl. CEO, in lieu of RSUs

DNA X, Inc.

Cash grant based on phantom RSUs valued at $60,000, vesting at earlier of 2027 annual meeting or change in control.
Grant made due to unavailability of shares under 2019 Equity Incentive Plan.
Payable at fair market value of common stock at vesting event.
All board members, including CEO Mike Mulica, receive the award.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.